Project Grant R43HL167440
Award Date
9/10/23
Completion Date
9/9/24
Dollars Obligated
$250K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded Antlia Bioscience, Inc. a Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) totaling $999,998.00 to develop a novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), for the treatment of resistant hypertension. The funding will support bulk manufacturing of the clinical-grade PAS(400)-hBNP compound, pharmacokinetic and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $715,110 to The Pennsylvania State University for the "Preclinical Evaluation of a Peptide-Amphiphile Derived Toroidal Oxygen Carrier" project. The goal is to design and optimize a blood substitute prototype (nano-RBC/nRBC) based on a deformable nanoparticle that is morphologically similar to red blood cells and can effectively...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This $299,504 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel therapeutic approach to clear small dense low-density lipoprotein (sdLDL) from circulation. The award recipient, Imetabolic Biopharma Corp, is conducting proof-of-concept Phase I research on re-engineering an existing APOC-III antagonist to incorporate APOE mimetic peptides. This dual-domain therapeutic...
The $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Functional Fluidics Inc.'s development of a rapid, integrated test for assessing red blood cell sickling in sickle cell disease. The key product is a stand-alone, potentially CLIA-waived point-of-care device with disposable cartridges to monitor patient condition and treatment efficacy, especially for drugs affecting...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $146,876 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Coriell Institute for Medical Research, Inc. The award, with a performance period from September 15, 2024 to July 31, 2026, aims to expand functional hematopoietic stem cells (HSCs) derived from human umbilical cord blood (UCB) for therapeutic applications. The research will utilize cryopreserved UCB samples from the NHLBI biospecimen...
Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $548,708 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oncoarendi Therapeutics LLC. The grant's objective is to develop a novel, disease-modifying oral medication for idiopathic pulmonary fibrosis (IPF) that targets the myocardin-related transcription factor (MRTF) pathway. The key goals of this Phase I project are to optimize a lead compound...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837). The goal of this 17-month grant, with an end date of February 28, 2025, is to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. Novomedix has developed a series of small molecule compounds that inhibit...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...